Galapagos NV ADR Cash Flow Conversion Efficiency
Galapagos NV ADR cash flow conversion efficiency. Based on the latest financial reports, Galapagos NV ADR (GLPG) has a cash flow conversion efficiency ratio of -0.025x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-82.75 Million) by net assets ($3.25 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Galapagos NV ADR (2004–2025)
Cash flow conversion efficiency of Galapagos NV ADR from 2004 to 2025. This chart illustrates how Galapagos NV ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Galapagos NV ADR for real-time trading data and today's change.
Galapagos NV ADR Cash Flow Conversion Ratio Explained
Galapagos NV ADR cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Galapagos NV ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Galapagos NV ADR ranked by their cash flow conversion efficiency. Also see GLPG company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Primaris Retail R.E. Invest. Tr. Units
TO:PMZ-UN
|
0.024x |
|
Sinbon Electronics Co Ltd
TW:3023
|
0.040x |
|
Stolt-Nielsen Limited
OL:SNI
|
0.039x |
|
Palvella Therapeutics, Inc
NASDAQ:PVLA
|
-0.059x |
|
Sai Gon Ha Noi Commercial Joint Stock Bank
VN:SHB
|
0.245x |
|
Horace Mann Educators Corporation
NYSE:HMN
|
0.149x |
|
Sparebank 1 Nord-Norge
OL:NONG
|
0.132x |
|
Jangho Group Co Ltd
SHG:601886
|
0.043x |
Annual Cash Flow Conversion Efficiency for Galapagos NV ADR (2004–2025)
The table below shows the annual cash flow conversion efficiency of Galapagos NV ADR from 2004 to 2025. Review Galapagos NV ADR free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.23 Billion | $-189.23 Million | -0.059x | +47.04% |
| 2024-12-31 | $2.90 Billion | $-320.03 Million | -0.110x | +23.93% |
| 2023-12-31 | $2.80 Billion | $-405.97 Million | -0.145x | +26.71% |
| 2022-12-31 | $2.53 Billion | $-500.54 Million | -0.198x | -3.96% |
| 2021-12-31 | $2.64 Billion | $-503.83 Million | -0.191x | -19.10% |
| 2020-12-31 | $2.67 Billion | $-427.34 Million | -0.160x | -112.79% |
| 2019-12-31 | $2.88 Billion | $3.60 Billion | 1.251x | +1166.08% |
| 2018-12-31 | $1.21 Billion | $-142.47 Million | -0.117x | +19.24% |
| 2017-12-31 | $1.01 Billion | $-147.03 Million | -0.145x | -146.04% |
| 2016-12-31 | $758.70 Million | $239.40 Million | 0.316x | +200.51% |
| 2015-12-31 | $365.00 Million | $-114.59 Million | -0.314x | +14.35% |
| 2014-12-31 | $206.13 Million | $-75.56 Million | -0.367x | -11835.82% |
| 2013-12-31 | $167.14 Million | $522.00K | 0.003x | -99.42% |
| 2012-12-31 | $118.45 Million | $64.10 Million | 0.541x | +634.28% |
| 2011-12-31 | $118.38 Million | $-11.99 Million | -0.101x | +19.01% |
| 2010-12-31 | $148.51 Million | $-18.57 Million | -0.125x | -316.03% |
| 2009-12-31 | $108.88 Million | $6.30 Million | 0.058x | +159.47% |
| 2008-12-31 | $84.32 Million | $-8.21 Million | -0.097x | -2687.95% |
| 2007-12-31 | $98.63 Million | $371.00K | 0.004x | +104.43% |
| 2006-12-31 | $109.54 Million | $-9.31 Million | -0.085x | -33.68% |
| 2005-12-31 | $61.14 Million | $-3.89 Million | -0.064x | +75.68% |
| 2004-12-31 | $10.37 Million | $-2.71 Million | -0.261x | -- |
About Galapagos NV ADR
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product c… Read more